IDRA logo

Idera Pharmaceuticals (IDRA) Cash From Financing

Annual CFF

$19.41 M
-$9.26 M-32.29%

December 31, 2021

Summary

Performance

1-Year Change

-32.29%

3-Year Change

+90.47%

5-Year Change

-67.18%

15-Year Change

-67.18%

IDRA Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$83.02 M
IDRA annual cash flow from financing activities is currently -76.62% below its historical high of $83.02 million

3-Year Low

$19.41 M
IDRA annual cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2021
IDRA previous annual earnings announcement was published on Dec 31, 2021

Next Annual Earnings Report Date

N/A
IDRA next annual earnings announcement has not yet been scheduled

OtherIDRAcash flowmetrics:

Annual CFI

$4.50 M
IDRA annual cash flow from investing activities is $4.50 million

Annual CFO

-$24.60 M
IDRA annual cash flow from operations is -$24.60 million

Annual FCF

-$24.60 M
IDRA annual free cash flow is -$24.60 million

Annual CAPEX

-
IDRA annual capital expenditures value is unknown

Quarterly CFF

$31.00 K
+$19.00 K+158.33%

September 30, 2022

Summary

Performance

3-Month Change

+158.33%

1-Year Change

-95.62%

3-Year Change

+6.9%

5-Year Change

+444.44%

IDRA Quarterly CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$81.19 M
IDRA quarterly cash flow from financing activities is currently -99.96% below its historical high of $81.19 million

3-Year Low

-$5000.00

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2022
IDRA previous earnings announcement was published on Sep 30, 2022

Next Quarterly Earnings Report Date

N/A
IDRA next earnings announcement has not yet been scheduled

OtherIDRAcash flowmetrics:

Quarterly CFI

$5.48 M
IDRA quarterly cash flow from investing activities is $5.48 million

Quarterly CFO

-$3.20 M
IDRA quarterly cash flow from operations is -$3.20 million

Quarterly FCF

-$3.20 M
IDRA quarterly free cash flow is -$3.20 million

Quarterly CAPEX

-
IDRA quarterly capital expenditures value is unknown

TTM CFF

$54.00 K
-$676.00 K-92.60%

September 30, 2022

Summary

Performance

3-Month Change

-92.6%

1-Year Change

-99.85%

3-Year Change

-99.65%

5-Year Change

-99.65%

IDRA TTM CFF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$85.61 M
IDRA TTM cash flow from financing activities is currently -99.94% below its historical high of $85.61 million

3-Year Low

$54.00 K
IDRA TTM cash flow from financing activities is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2022
IDRA previous earnings announcement was published on Sep 30, 2022

Next Quarterly Earnings Report Date

N/A
IDRA next earnings announcement has not yet been scheduled

OtherIDRAcash flowmetrics:

TTM CFI

$5.48 M
IDRA TTM cash flow from investing activities is $5.48 million

TTM CFO

-$15.34 M
IDRA TTM cash flow from operations is -$15.34 million

TTM FCF

-$15.34 M
IDRA TTM free cash flow is -$15.34 million

TTM CAPEX

-
IDRA TTM capital expenditures value is unknown

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

IDRA Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-32.3%-95.6%-99.8%
3 y3 years+90.5%+6.9%-99.7%
5 y5 years-67.2%+444.4%-99.7%

IDRA Cash From Financing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat highat lowat high-116.1%-99.7%at low
5 y5-year-32.3%-20.2%-99.8%-116.1%-99.9%at low
alltimeall time-76.6%-114.5%-100.0%<-9999.0%-99.9%<-9999.0%

Idera Pharmaceuticals Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2022
-
$31.00 K(+158.3%)
$54.00 K(-92.6%)
Jun 2022
-
$12.00 K(-25.0%)
$730.00 K(-75.9%)
Mar 2022
-
$16.00 K(-420.0%)
$3.03 M(-84.4%)
Dec 2021
$19.41 M(-32.3%)
-$5000.00(-100.7%)
$19.41 M(-45.7%)
Sep 2021
-
$707.00 K(-69.4%)
$35.74 M(-10.9%)
Jun 2021
-
$2.31 M(-85.9%)
$40.10 M(-8.1%)
Mar 2021
-
$16.40 M(+0.5%)
$43.64 M(+52.2%)
Dec 2020
$28.67 M(+85.1%)
$16.33 M(+222.8%)
$28.67 M(+20.0%)
Sep 2020
-
$5.06 M(-13.6%)
$23.88 M(+26.7%)
Jun 2020
-
$5.85 M(+309.0%)
$18.85 M(+23.1%)
Mar 2020
-
$1.43 M(-87.6%)
$15.31 M(-1.1%)
Dec 2019
$15.49 M(+52.0%)
$11.54 M(>+9900.0%)
$15.49 M(+288.7%)
Sep 2019
-
$29.00 K(-98.7%)
$3.98 M(-0.4%)
Jun 2019
-
$2.31 M(+44.2%)
$4.00 M(+81.3%)
Mar 2019
-
$1.60 M(+4237.8%)
$2.21 M(-78.4%)
Dec 2018
$10.19 M(-82.8%)
$37.00 K(-15.9%)
$10.19 M(-85.2%)
Sep 2018
-
$44.00 K(-91.5%)
$69.05 M(+0.1%)
Jun 2018
-
$520.00 K(-94.6%)
$69.00 M(+0.3%)
Mar 2018
-
$9.59 M(-83.7%)
$68.77 M(+16.2%)
Dec 2017
$59.16 M(+16.2%)
$58.89 M(<-9900.0%)
$59.16 M(+15.4%)
Sep 2017
-
-$9000.00(-103.1%)
$51.27 M(+0.0%)
Jun 2017
-
$289.00 K(-1800.0%)
$51.26 M(+0.6%)
Mar 2017
-
-$17.00 K(-100.0%)
$50.93 M(+0.0%)
Dec 2016
$50.92 M(-38.7%)
$51.01 M(<-9900.0%)
$50.92 M(+3516.3%)
Sep 2016
-
-$23.00 K(-36.1%)
$1.41 M(-30.0%)
Jun 2016
-
-$36.00 K(+24.1%)
$2.01 M(+12.0%)
Mar 2016
-
-$29.00 K(-101.9%)
$1.80 M(-97.8%)
Dec 2015
$83.02 M(+82.0%)
$1.50 M(+157.5%)
$83.02 M(+1.7%)
Sep 2015
-
$581.00 K(-331.5%)
$81.60 M(-1.7%)
Jun 2015
-
-$251.00 K(-100.3%)
$83.04 M(-1.3%)
Mar 2015
-
$81.19 M(>+9900.0%)
$84.10 M(+84.4%)
Dec 2014
$45.62 M(+6.9%)
$82.00 K(-95.9%)
$45.62 M(-2.7%)
Sep 2014
-
$2.02 M(+146.8%)
$46.86 M(-34.9%)
Jun 2014
-
$817.00 K(-98.1%)
$71.96 M(-15.9%)
Mar 2014
-
$42.70 M(+3117.8%)
$85.61 M(+100.7%)
Dec 2013
$42.66 M(+684.0%)
$1.33 M(-95.1%)
$42.66 M(-9.6%)
Sep 2013
-
$27.12 M(+87.6%)
$47.20 M(+137.0%)
Jun 2013
-
$14.46 M(-5953.8%)
$19.91 M(+276.0%)
Mar 2013
-
-$247.00 K(-104.2%)
$5.30 M(-2.7%)
Dec 2012
$5.44 M(-40.3%)
$5.87 M(-3720.4%)
$5.44 M(-37.1%)
Sep 2012
-
-$162.00 K(+1.3%)
$8.65 M(-1.9%)
Jun 2012
-
-$160.00 K(+56.9%)
$8.82 M(-2.0%)
Mar 2012
-
-$102.00 K(-101.1%)
$8.99 M(-1.3%)
Dec 2011
$9.12 M(-35.8%)
$9.08 M(>+9900.0%)
$9.12 M(>+9900.0%)
Sep 2011
-
$4000.00(-75.0%)
$62.00 K(-99.6%)
Jun 2011
-
$16.00 K(-15.8%)
$14.18 M(-0.1%)
Mar 2011
-
$19.00 K(-17.4%)
$14.19 M(-0.1%)
DateAnnualQuarterlyTTM
Dec 2010
$14.20 M(+5943.0%)
$23.00 K(-99.8%)
$14.20 M(-0.2%)
Sep 2010
-
$14.12 M(>+9900.0%)
$14.22 M(+9018.6%)
Jun 2010
-
$27.00 K(-20.6%)
$156.00 K(-22.8%)
Mar 2010
-
$34.00 K(-27.7%)
$202.00 K(-14.0%)
Dec 2009
$235.00 K(-97.3%)
$47.00 K(-2.1%)
$235.00 K(-38.5%)
Sep 2009
-
$48.00 K(-34.2%)
$382.00 K(-89.9%)
Jun 2009
-
$73.00 K(+9.0%)
$3.77 M(-34.4%)
Mar 2009
-
$67.00 K(-65.5%)
$5.75 M(-34.4%)
Dec 2008
$8.77 M(+203.0%)
$194.00 K(-94.4%)
$8.77 M(-9.4%)
Sep 2008
-
$3.44 M(+67.4%)
$9.69 M(+50.5%)
Jun 2008
-
$2.05 M(-33.5%)
$6.43 M(+11.1%)
Mar 2008
-
$3.09 M(+178.6%)
$5.79 M(+100.0%)
Dec 2007
$2.90 M(-89.6%)
$1.11 M(+495.7%)
$2.90 M(-84.0%)
Sep 2007
-
$186.00 K(-86.8%)
$18.04 M(-15.6%)
Jun 2007
-
$1.41 M(+638.2%)
$21.37 M(+7.4%)
Mar 2007
-
$191.00 K(-98.8%)
$19.89 M(-28.7%)
Dec 2006
$27.89 M(+490.5%)
$16.25 M(+362.9%)
$27.89 M(+139.6%)
Sep 2006
-
$3.51 M(-5420.2%)
$11.64 M(+43.0%)
Jun 2006
-
-$66.00 K(-100.8%)
$8.14 M(-36.8%)
Mar 2006
-
$8.19 M(>+9900.0%)
$12.88 M(+172.8%)
Dec 2005
$4.72 M(-66.9%)
$6000.00(-48.7%)
$4.72 M(+0.2%)
Sep 2005
-
$11.70 K(-99.7%)
$4.71 M(-50.0%)
Jun 2005
-
$4.68 M(>+9900.0%)
$9.43 M(-33.6%)
Mar 2005
-
$28.90 K(-1304.2%)
$14.20 M(-0.4%)
Dec 2004
$14.25 M(+83.4%)
-$2400.00(-100.1%)
$14.25 M(+0.0%)
Sep 2004
-
$4.73 M(-50.0%)
$14.25 M(-37.0%)
Jun 2004
-
$9.45 M(>+9900.0%)
$22.60 M(+71.6%)
Mar 2004
-
$79.70 K(-2254.1%)
$13.17 M(+69.5%)
Dec 2003
$7.77 M(+8003.1%)
-$3700.00(-100.0%)
$7.77 M(+3.9%)
Sep 2003
-
$13.08 M(>+9900.0%)
$7.48 M(-232.9%)
Jun 2003
-
$18.30 K(-100.3%)
-$5.63 M(+6.9%)
Mar 2003
-
-$5.32 M(+1682.6%)
-$5.26 M(-5590.4%)
Dec 2002
$95.90 K(-137.7%)
-$298.60 K(+1239.0%)
$95.80 K(-93.6%)
Sep 2002
-
-$22.30 K(-105.8%)
$1.50 M(-243.4%)
Jun 2002
-
$383.80 K(+1066.6%)
-$1.05 M(-79.9%)
Mar 2002
-
$32.90 K(-97.0%)
-$5.22 M(+1953.5%)
Dec 2001
-$254.40 K(-90.9%)
$1.11 M(-143.1%)
-$254.40 K(-95.8%)
Sep 2001
-
-$2.57 M(-32.2%)
-$6.00 M(+93.4%)
Jun 2001
-
-$3.79 M(-175.8%)
-$3.10 M(-468.8%)
Mar 2001
-
$5.00 M(-207.9%)
$841.30 K(-130.0%)
Dec 2000
-$2.81 M(-150.1%)
-$4.64 M(-1527.0%)
-$2.81 M(-253.2%)
Sep 2000
-
$325.00 K(+114.7%)
$1.83 M(+21.6%)
Jun 2000
-
$151.40 K(-88.8%)
$1.51 M(+11.2%)
Mar 2000
-
$1.36 M
$1.36 M
Dec 1999
$5.60 M(-72.5%)
-
-
Dec 1998
$20.39 M(-54.1%)
-
-
Dec 1997
$44.44 M(-32.2%)
-
-
Dec 1996
$65.53 M
-
-

FAQ

  • What is Idera Pharmaceuticals annual cash flow from financing activities?
  • What is the all time high annual CFF for Idera Pharmaceuticals?
  • What is Idera Pharmaceuticals annual CFF year-on-year change?
  • What is Idera Pharmaceuticals quarterly cash flow from financing activities?
  • What is the all time high quarterly CFF for Idera Pharmaceuticals?
  • What is Idera Pharmaceuticals quarterly CFF year-on-year change?
  • What is Idera Pharmaceuticals TTM cash flow from financing activities?
  • What is the all time high TTM CFF for Idera Pharmaceuticals?
  • What is Idera Pharmaceuticals TTM CFF year-on-year change?

What is Idera Pharmaceuticals annual cash flow from financing activities?

The current annual CFF of IDRA is $19.41 M

What is the all time high annual CFF for Idera Pharmaceuticals?

Idera Pharmaceuticals all-time high annual cash flow from financing activities is $83.02 M

What is Idera Pharmaceuticals annual CFF year-on-year change?

Over the past year, IDRA annual cash flow from financing activities has changed by -$9.26 M (-32.29%)

What is Idera Pharmaceuticals quarterly cash flow from financing activities?

The current quarterly CFF of IDRA is $31.00 K

What is the all time high quarterly CFF for Idera Pharmaceuticals?

Idera Pharmaceuticals all-time high quarterly cash flow from financing activities is $81.19 M

What is Idera Pharmaceuticals quarterly CFF year-on-year change?

Over the past year, IDRA quarterly cash flow from financing activities has changed by -$676.00 K (-95.62%)

What is Idera Pharmaceuticals TTM cash flow from financing activities?

The current TTM CFF of IDRA is $54.00 K

What is the all time high TTM CFF for Idera Pharmaceuticals?

Idera Pharmaceuticals all-time high TTM cash flow from financing activities is $85.61 M

What is Idera Pharmaceuticals TTM CFF year-on-year change?

Over the past year, IDRA TTM cash flow from financing activities has changed by -$35.69 M (-99.85%)